Alnylam price target raised to $459 from $385 at Truist

Truist raised the firm’s price target on Alnylam (ALNY) to $459 from $385 and keeps a Buy rating on the shares. The firm is updating its model after the company’s Q2 earnings beat, the analyst tells investors in a research note. The significant FY25 guidance raise also suggests Amvuttra’s ATTR-CM launch trajectory is already outpacing Truist’s prior bullish projections, the firm added.